Network in pediatric rheumatology: The example of the Pediatric Rheumatology International Trials Organization

World Journal of Pediatrics

Volumn 4, Issue 3, 2008, Pages 186-191

  Ruperto, Nicolino ^a   Martini, Alberto ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Clinical trials; Collaborative research; Pediatric rheumatic diseases; Quality of life

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLD SALT; HYDROXYCHLOROQUINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE;

ACCESS TO INFORMATION; CHILD HEALTH CARE; CHILDHOOD DISEASE; CHILDHOOD HEALTH ASSESSMENT QUESTIONNAIRE; CHILDHOOD HEALTH QUESTIONNAIRE; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; DERMATOMYOSITIS; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; ERYTHROCYTE SEDIMENTATION RATE; EVIDENCE BASED MEDICINE; HUMAN; INTERNET; JUVENILE RHEUMATOID ARTHRITIS; MEDICAL EDUCATION; MEDICAL INFORMATION; MEDICAL RESEARCH; MEDICAL SOCIETY; METHODOLOGY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; QUALITY CONTROL; QUALITY OF LIFE; QUESTIONNAIRE; REMISSION; REVIEW; RHEUMATIC DISEASE; RHEUMATOLOGY; STANDARDIZATION; SYSTEMIC LUPUS ERYTHEMATOSUS; VALIDATION STUDY;

ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CLINICAL TRIALS AS TOPIC; HUMANS; PEDIATRICS; QUALITY OF LIFE; RESEARCH; RHEUMATIC DISEASES; RHEUMATOLOGY; WORLD HEALTH;

EID: 55649118445     PISSN: 17088569     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12519-008-0034-6     Document Type: Review

References (54)

1. Allaire SH, DeNardo BS, Szer IS, Meenan RF, Schaller JG. The economic impacts of juvenile rheumatoid arthritis. J Rheumatol 1992;19:952-955.
2. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007;369:767-778.
3. Ruperto N, Levinson JE, Ravelli A, Shear ES, Tague BL, Murray K, et al. Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis. I. Outcome status. J Rheumatol 1997;24:945-951.
4. Ruperto N, Ravelli A, Levinson JE, Shear ES, Murray K, Tague BL, et al. Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis. II. Early predictors of outcome. J Rheumatol 1997;24:952-958.
5. Gutiérrez-Suárez R, Ruperto N, Gastaldi R, Pistorio A, Felici E, Burgos-Vargas R, et al. A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. Arthritis Rheum 2006;54:2989-2996.
6. Rothman KJ, Michels KB. The continuing unethical use of placebo controls. N Engl J Med 1994;331:394-398.
7. Schechter C. The use of placebo controls. N Engl J Med 1995;332:60-61.
8. Taubes G. Medical research: Use of placebo controls in clinical trials disputed. Science 1995;267:25-26.
9. Reiff A, Shaham B, Wood BP, Bernstein BH, Stanley P, Szer IS. High dose methotrexate in the treatment of refractory juvenile rheumatoid arthritis. Clin Exp Rheumatol 1995;13:113-118.
10. Wallace CA, Sherry DD. Preliminary report of higher dose methotrexate treatment in juvenile rheumatoid arthritis. J Rheumatol 1992;19:1604-1607.
11. Miller LC, Sisson BA, Tucker LB, DeNardo BA, Schaller JG. Methotrexate treatment of recalcitrant childhood dermatomyositis. Arthritis Rheum 1992;35:1143-1149.
12. Lovell DJ, Giannini EH, Brewer EJ. Time course of response to nonsteroidal antiinflammatory drugs in juvenile rheumatoid arthritis. Arthritis Rheum 1984;27:1433-1437.
13. Brewer EJ, Giannini EH. Methodology and studies of children with juvenile rheumatoid arthritis. J Rheumatol 1982;9:107-139.
14. Brewer EJ, Giannini EH. Standard methodology for segment I, II, and III pediatric rheumatology collaborative study group studies. I. Design. J Rheumatol 1982;9:109-113.
15. Giannini EH, Brewer EJ. Standard methodology for segment I, II, and III pediatric rheumatology collaborative study group studies. II. Analysis and presentation of data. J Rheumatol 1982;9:114-122.
16. Giannini EH. The N of 1 trials design in the rheumatic diseases. Arthritis Care Res 1988;1:109-115.
17. Giannini EH, Cassidy JT, Brewer EJ, Shaikov A, Maximov A, Kuzmina N. Comparative efficacy and safety of advanced drug therapy in children with juvenile rheumatoid arthritis. Semin Arthritis Rheum 1993;23:34-46.
18. Giannini EH, Brewer EJ, Person DA. Auranofin in the treatment of juvenile rheumatoid arthritis. J Pediatr 1983;102:138-141.
19. Brewer EJ, Giannini EH, Kuzmina N, Alekseev L. Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis: Results of the U.S.A.-U.S.S.R double-blind, placebo controlled trial. N Engl J Med 1986;314:1269-1276.
20. Giannini EH, Brewer EJ Jr, Kuzmina N, Shaikov A, Wallin B. Auranofin in the treatment of juvenile rheumatoid arthritis. Results of the USA-USSR double-blind, placebo-controlled trial. The USA Pediatric Rheumatology Collaborative Study Group. The USSR Cooperative Children's Study Group. Arthritis Rheum 1990;33:466-476.
21. Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. N Engl J Med 1992;326:1043-1409.
22. Lovell DJ, Giannini EH, Reiff A, Cawkwell D, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000;342:763-769.
23. Advisory Council of PRINTO. Bylaws of the "Paediatric Rheumatology International Trials Organisation-PRINTO". First ed. June 15th, 1997. Second ed. October 1st, 2003. Available at www.printo.it (January 25, 2008).
24. Ruperto N, Martini A. International research networks in pediatric rheumatology: The PRINTO perspective. Curr Opin Rheumatol 2004;16:566-570.
25. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202.
26. Ruperto N, Ravelli A, Falcini F, Lepore L, De Sanctis R, Zulian F, et al. Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate. Italian Pediatric Rheumatology Study Group. Ann Rheum Dis 1998;57:38-41.
27. Albornoz MA. ACR formally adopts improvement criteria for juvenile arthritis (ACR Pediatric 30). ACR News 2002;21:3.
28. Ruperto N, Murray KJ, Gerloni V, Wulffraat N, de Oliveira SKF, Falcini F, et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004;50:2191-2201.
29. Martini A, Ruperto N, for the Paediatric Rheumatology International Trials Organization (PRINTO). Quality of life in juvenile idiopathic arthritis patients compared to healthy children. Clin Exp Rheumatol 2001;19:S1-S172.
30. Ruperto N, Ravelli A, Pistorio A, Malattia C, Cavuto S, Gado-West L, et al. Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries. Review of the general methodology. Clin Exp Rheumatol 2001;19:S1-S9.
31. Pagava K, Ruperto N, Shalamberidze L, Mshvidobadze N, Paediat Rheumatology Int Trials Or. The Georgian version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol 2001;19:S66-S70.
32. Ruperto N, Buratti S, Duarte-Salazar C, Pistorio A, Reiff A, Bernstein B, et al. Health-related quality of life in juvenile-onset systemic lupus erythematosus and its relationship to disease activity and damage. Arthritis Rheum 2004;51:458-464.
33. Gutierrez-Suarez R, Pistorio A, Cespedes CA, Norambuena X, Flato B, Rumba I, et al. Health-related quality of life of patients with juvenile idiopathic arthritis coming from 3 different geographic areas. The PRINTO multinational quality of life cohort study. Rheumatology 2007;46:314-320.
34. Oliveira S, Ravelli A, Pistorio A, Castell E, Malattia C, Prieur AM, et al. Proxy-reported health-related quality of life of patients with juvenile idiopathic arthritis: The Pediatric Rheumatology International Trials Organization multinational quality of life cohort study. Arthritis Rheum 2007;57:35-43.
35. Apaz M, Pistorio A, Ravelli A, Trail L, Cuttica R, Sato J, et al. Health related quality of life of patients with juvenile dermatomyositis. The PRINTO multinational quality of life cohort study. Ann Rheum Dis 2006;65:244.
36. Ruperto N, Ravelli A, Murray KJ, Lovell DJ, Andersson-Gare B, Feldman BM, et al. Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology (Oxford) 2003;42:1452-1459.
37. Ruperto N, Ravelli A, Cuttica R, Espada G, Ozen S, Porras O, et al. The Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: Prospective validation of the disease activity core set. Arthritis Rheum 2005;52:2854-2864.
38. Ruperto N, Ravelli A, Pistorio A, Ferriani V, Calvo I, Ganser G, et al. The provisional Pediatric Rheumatology International Trial Organization/ American College of Rheumatology/European League Againts Rheumatism disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: A prospective validation study. Arthritis Rheum 2008;59:4-13.
39. Ruperto N, Ravelli A, Oliveira S, Alessio M, Mihaylova D, Pasic S, et al. The Pediatric Rheumatology International Trials Organization/ American College of Rheumatology provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus. Prospective validation of the definition of improvement. Arthritis Rheum 2006;55:355-363.
40. Ruperto N, Garcia-Munitis P, Villa L, Pesce M, Aggarwal A, Fasth A, et al. PRINTO/PRES international website for families of children with rheumatic diseases: www.pediatricrheumatology.printo.it. Ann Rheum Dis 2005;64:1101-1106.
41. Hirsch R. Pediatric rheumatology: A call to action. Curr Opin Rheumatol 2004;15:571.
42. Bandeira M, Falcone A, Pistorio A, Ruperto N, Magni-Manzoni S, Buoncompagni A, et al. Weighting improves the information provided by joint counts on the severity of arthritis and its impact on patients' well-being in juvenile idiopathic arthritis. Rheumatology 2006;45:343-347.
43. Ferriani VPL, Ruperto N, Pistorio A, Oliveira S, Pilkington C, Magalhaes C, et al. Toward the development of a new PRINTO disease activity index for juvenile dermatomyositis. I. Selection of the candidate items based on the analysis of 284 patients. Ann Rheum Dis 2006;65:250.
44. Garcia-Munitis P, Bandeira M, Pistorio A, Magni-Manzoni S, Ruperto N, Schivo A, et al. Level of agreement between children, parents, and physicians in rating pain intensity in juvenile idiopathic arthritis. Arthritis Rheum 2006;55:177-183.
45. Sztajnbok F, Coronel-Martinez DL, az-Maldonado A, Novarini C, Pistorio A, Viola S, et al. Discordance between physician's and parent's global assessments in juvenile idiopathic arthritis. Rheumatology 2006;46:141-145.
46. Tsitsami E, Bozzola E, Magni-Manzoni S, Viola S, Pistorio A, Ruperto N, et al. Positive family history of psoriasis does not affect the clinical expression and course of juvenile idiopathic arthritis patients with oligoarthritis. Arthritis Rheum 2003;49:488-493.
47. Wallace CA, Ruperto N, Giannini E, Childhood Arthritis and Rheumatology Research Alliance, Pediatric Rheumatology International Trials Organization, Pediatric Rheumatology Collaborative Study Group. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004;31:2290-2294.
48. Connor JD. A look at the future of pediatric therapeutics: An investigator's perspective of the new pediatric rule. Pediatrics 1999;104:610-613.
49. Food and Drug Administration (FDA). Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biologic products in pediatrics patients (21 CFR Parts 201, 312, 314, and 601). Federal Register 1998;63(231).
50. Ruperto N, Martini A. Use of unlabelled and off licence drugs in children. A European paediatric rule is needed to protect children. BMJ 2000;320:1210-1211.
51. Regulation (EC) no 1901/2006 of the European parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. Official J Eur Union 2006;378:1-19.
52. Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticularcourse juvenile rheumatoid arthritis. Arthritis Rheum 2007;56:3096-3106.
53. Ruperto N, Lovell DJ, Prieur AM, Paz E, Rubio Perez NE, Silva CA, et al. Efficacy and safety of abatacept in children and adolescents with active juvenile idiopathic arthritis (JIA). Lancet. In Press 2008.
54. Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Nemcova D, et al. 48-week data from the study of adalimumab in children with juvenile rheumatoid arthritis (JRA). N Engl J Med. In Press 2008.